header logo image


Page 1,048«..1020..1,0471,0481,0491,050..1,0601,070..»

Puma Biotechnology Inc (PBYI) Plunges 9.45% on March 21 – Equities.com

March 21st, 2017 6:49 pm

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a rough trading day for Tuesday March 21 as shares tumbled 9.45%, or a loss of $-4.2 per share, to close at $40.25. After opening the day at $44.75, shares of Puma Biotechnology Inc traded as high as $44.85 and as low as $39.80. Volume was 947,068 shares over 8,315 trades, against an average daily volume of 991,915 shares and a total float of 36.95 million.

As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.49 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $36.22 and 200-day SMA is $42.55.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read the original here:
Puma Biotechnology Inc (PBYI) Plunges 9.45% on March 21 - Equities.com

Read More...

Biodiversity, Biotechnology and Intellectual Property: their relevance for the development of Colombia – Lexology (registration)

March 21st, 2017 6:49 pm

Biotechnology has emerged as one of the most forward-looking fields of science in recent decades, and a large number of nations have set their sights on it as a long-term development pillar, given its wide range of applications and the leapfrogging of current information technology, which allows to further exploit its potential.

Biotechnology has already proven to be an option for growth in multiple economic sectors, finding applications of high importance in sectors such as pharmaceuticals, food, veterinary, cosmetic, environmental, agricultural, energy, among others, which make it an opportunity for those developing countries in search of a boost for the progress of their economies.

It is then in biotechnology that a country like Colombia, which occupies the second place after Brazil in world biodiversity, with around 10% of the fauna and flora of the planet, can find possibilities of great impact for its economic growth and technological development. However, it is not a simple challenge if one takes into account the little investment that, unfortunately, is destined for R&D in the country. For example, according to World Bank data for the year 2014, Colombia allocated about 0.2% of GDP for this purpose, an amount significantly lower than the world average of about 2%, and much lower than the number one country in this regard, South Korea, which investment in R&D is above 4% of GDP.

In this manner, the government, academics and companies must work together to transform this enormous biodiversity into a factory of knowledge and innovation that translates into solutions to both local and global problems, which in the long term will allow to narrow the economic-technological gap between Colombia and the most developed countries in the world.

Thus, in the commitment to research in general as a driving force for development, and in particular concerning the emerging biotechnology, intellectual property plays a decisive role for its progress; this is due to the fact that tools for the protection of inventions, such as patents, greatly influence the decision of companies to invest or not their capital in a particular sector, and even more in biotechnology, which is undoubtedly one of those with highest cost in both R&D and product development and process design.

Hence, it is possible to evidence in different countries a closely related upward trend between R&D spending and the filing of patent applications, making them a clear indicator of a country's innovation and inventive step. By way of example, this is clearly visible when comparing the number of patent applications filed in Colombia and South Korea, using data provided by the World Bank in this regard for the same year mentioned above. In Colombia, in 2014, 260 patent applications were filed by residents and 1898 by non-residents; values much lower than those in South Korea where the numbers amount to 164073 patent applications filed by residents and 46219 by non-residents for the same year.

Therefore, it is necessary a vision change from the government of Colombia that promotes the injection of public and private capital in R&D, which is supported by an intellectual property system that provides adequate legal protection to the inventions and compensates the economic efforts made in innovation. Taking into account the characteristics of the country, Colombia has the potential to establish, as one of the pillars of its economy, its own biodiversity together with biotechnology; however, to this day, this latter is greatly underestimated.

In this sense, the challenge for Colombia in the coming years is to recognize and take advantage of the immense potential for scientific research that it possesses, especially in terms of biotechnology, in order to have in the future the ability to offer products and services with high standards of quality and added value, derived from a sustainable exploitation of its natural resources that goes hand in hand with policies ensuring the technical, legal and economic conditions conducive to its realization.

Continue reading here:
Biodiversity, Biotechnology and Intellectual Property: their relevance for the development of Colombia - Lexology (registration)

Read More...

Assessing biotechnology in the age of cloud computing – Cloud Tech

March 21st, 2017 6:49 pm

In order to ensure that patient outcomes are constantly being improved upon it is important that the speed of change within the biotechnology sector occurs at an exponential rate. However, this continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.

Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment. To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.

At iland, we have worked with many companies in the healthcare, life sciences and biotech industries. Therefore, we know from experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world. For example, we recently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the iland cloud. As a result, their DR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.

If you still need convincing here are three key benefits that we believe cloud brings to biotech organisations:

When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade. These days, thanks largely to cloud technology, it can bedone in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning. Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.

Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing 'black box' that obscures details needed to accurately interpret the results of computational analyses. In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications. Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.

Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily.For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed. At the same time biotechnologists need to be able to access and share data across multiple departments or even multiple companies.

Cloud computing in biotechnology makes this all possible. Theiland cloud, for instance, centralises data, ensuring security and data sovereignty while facilitating collaboration. It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.

Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues. Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.

As well as enhanced billing visibility and resource management functions, the release of our latest Secure Cloud Services means that the iland cloud now includes on-demand security and compliance reports. This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.

Without a shadow of a doubt, cloud technology can help biotechnology companies build the future.From research and development to marketing, computing affects everything your organisation does. With rich experience in the biotech, healthcare and life sciences sector, you should talk to iland today to find out how our cloud hosting services can give you the power to develop at the speed of thought, not the speed of compliance or processing.

Read more: Why the cloud could hold the cure to diseases

Visit link:
Assessing biotechnology in the age of cloud computing - Cloud Tech

Read More...

Macchiarini’s seventh transplant patient dies – The Local Italy

March 21st, 2017 1:46 am

Italian surgeon Paolo Macchiarini. Photo: AP Photo/Lorenzo Galassi

A seventh patient of Italian surgeon Paolo Macchiarini, who was fired from a Swedish university over accusations of misconduct, has died.

Macchiarini performed two synthetic trachea transplants on Yesim Cetir, 26, in Stockholm in 2012 and 2013, but she suffered brutal complications until her death.

In the early hours of Monday, her father Hayrullah Cetir announced on his Facebook account that Yesim died at Temple University Hospital in Philadelphia.

"My daughter Yesim died tonight [Sunday] at 9.15pm may she rest in peace," he wrote, publishing a picture of her in a hospital bed.

Macchiarini operated on eight patients between 2011 and 2014, three of them at the prestigious Stockholm-based Karolinska Institute, which selects the winners of the Nobel Prize in medicine.

Only one of the patients survived after having a synthetic trachea, designed and implanted by Macchiarini, removed during a surgery in Russia in 2014.

Cetir was the victim of two failed surgeries as her trachea was first badly damaged during treatment in Turkey before she received surgery in Stockholm.

She went to the United States to receive a trachea from a donor, without being able to recover.

"It is with great sorrow that I offer my sincere condolences to Yesim Cetir's family after having heard about her death. It would of course be inappropriate to discuss her earlier medical condition and treatment," Macchiarini said in a written comment to Swedish public broadcaster SVT.

The surgeon gained worldwide fame in 2011 by carrying out the world's first graft of an artificial plastic trachea, which was to be colonized by the patients' stem cells.

While he said in the medical journal The Lancet that the technique was working, successive deaths of his patients and falsifications in the article led him to be sacked.

Macchiarini was suspected of having embellished his resume to be hired by the Karolinska Institute. He is being investigated by Swedish police.

The scandal hit the Nobel Prize and caused several resignations within the institute.

Continue reading here:
Macchiarini's seventh transplant patient dies - The Local Italy

Read More...

Jailed Iranian researcher’s health worsening rapidly – Nature.com

March 21st, 2017 1:46 am

Courtesy of Vida Mehrannia

Ahmadreza Djalali, a researcher in disaster medicine, was arrested in Tehran in April 2016.

An Iranian researcher jailed in Tehran for the last 11 months is in declining health after spending more than two months on hunger strike. This month, researchers around the world made urgent appeals for his release.

Ahmadreza Djalali, a researcher in disaster medicine and a resident of Sweden, was arrested on an academic visit to Tehran in April 2016. On 11 March he was brought to a prison hospital after he refused to eat in protest at being threatened with the death sentence and at being denied his choice of lawyer. Djalali, who still awaits trial, has experienced kidney and heart pain and for a week in late February refused to take liquids, says his wife, Vida Merhannia. He has lost 30% of his body weight since he entered prison.

Djalali, 45, works on improving hospitals emergency responses to armed terrorism and radiological, chemical and biological threats. He has affiliations with Swedens Karolinska Institute in Stockholm and Italys University of Eastern Piedmont in Novara. But on 25 April 2016 he was arrested and accused of collaboration with a hostile government. According to his wife, he was kept in solitary confinement for three months, and forced to sign a confession.

Djalali began a first hunger strike in late December in protest against what he has told his wife is a false accusation. In late January, a judge on Irans revolutionary court threatened him with a death sentence. He stopped his strike on 15 February, but resumed it three days later after the judge ordered him to change his lawyer or choose a court-appointed one. His trial has not yet been scheduled.

On 9 March, Djalalis colleagues, together with the Committee of Concerned Scientists in New York and human-rights groups such as Amnesty International and Scholars at Risk, wrote to the Iranian authorities to ask that Djalali be given due legal process and released, unless charged with a recognizable criminal offence.

Djalalis case has drawn particular attention in Italy, in part because of his Eastern Piedmont connections. Parliamentarians there have protested to the Iranian ambassador, and Elena Cattaneo, a senator and stem-cell researchers at the University of Milan, said she would refuse to attend a July conference on stems cells in Iran in protest.

Its unclear why the Iranian government has arrested Djalali, says his colleague Luca Ragazzoni, a health researcher at the University of Eastern Piedmont, who worked with him from 2012 to 2015. In a separate case, physicist Omid Kokabee released from a Tehran jail in August 2016 after five years imprisonment believes he himself was punished for refusing to help a covert nuclear-weapons programme. But Ragazzoni says that disaster health research is less controversial. The data we work with are not sensitive, and we publish all our results: I dont see what else a government should be interested in, he says. He thinks the groups international collaborations may have raised suspicion.

The USIran nuclear deal in 2015 had sparked hopes of greater academic freedom in Iran. But since that agreement, other researchers besides Djalali have been imprisoned or sentenced. They include Homa Hoodfar, a CanadianIranian social anthropologist who was arrested in March 2016 and charged with dabbling in feminism and security matters, before being released on humanitarian grounds 112 days later; and retired Iranian polymer scientist Mohammad Hossein Rafiee-Fanood, who was sentenced to six years in prison in May 2015 for political activism, and was released on medical furlough last year.

Hamid Babaei, an Iranian mathematics student who was studying for a PhD in finance at the University of Lige in Belgium when he was arrested in August 2013, remains in prison on a six-year sentence for spying and contact with enemy states. He says that he was imprisoned for refusing to be an informant in Belgium for Irans intelligence ministry.

"Iranian scientists enjoy access to world institutions and the worldwide web of scientific information. But they do not enjoy freedom of political dissent. The nuclear deal has not changed this situation by an inch," says Eugene Chudnovsky, a physicist at the City University of New York who is co-chair of the Committee of Concerned Scientists.

The rest is here:
Jailed Iranian researcher's health worsening rapidly - Nature.com

Read More...

New trial for blindness rewrites the genetic code – Medical Xpress

March 21st, 2017 1:46 am

March 20, 2017 New trial for blindness rewrites the genetic code. Credit: Shutterstock

Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people.

Retinitis pigmentosa is currently untreatable and leads to a slow and irreversible loss of vision.

The trial is being run by Nightstarx Ltd (Nightstar), a biopharmaceutical spinout company of Oxford developing gene therapies for inherited retinal diseases, and researchers from the University of Oxford. On 16 March 2017, a 29 year old British man became the first patient with X-linked retinitis pigmentosa to undergo gene therapy. The operation took place at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Foundation Trust.

Gene therapy uses a virus to insert the correct copy of a defective gene into cells, and has shown promise for treating genetic causes of blindness. Unfortunately, the gene involved with retinitis pigmentosa, RPGR, is highly unstable, making gene therapy particularly challenging. The RPGR gene's unusual genetic code has made it very difficult to work with in the laboratory.

However, a research team led by Professor Robert MacLaren from the University of Oxford has reprogrammed the genetic code of RPGR to make it more stable, but in a way that does not affect its function. This has allowed the gene to be delivered reliably by a viral vector into retinal cells.

The current trial is the first in the world to test a treatment for retinitis pigmentosa caused by RPGR.

Robert MacLaren, Professor of Ophthalmology at the University of Oxford, who is leading the trial said: "The effect of RPGR-related disease on families with retinitis pigmentosa is devastating and we have spent many years working out how to develop this gene therapy. Changing the genetic code is always undertaken with great caution, but the new sequence we are using has proven to be highly effective in our laboratory studies.

"The genetic code for all life on Earth is made up of four letters G, T, A and C. In RPGR, however, half of the gene comprises only two letters A and G. This makes the gene very unstable and prone to mutations, making it a lead cause of blindness in patients with retinitis pigmentosa. RPGR is vital for the light sensitive cells at the back of the eye."

The trial has started at the Oxford University Hospitals NHS Foundation Trust and is sponsored by Nightstar, a University of Oxford spin-out company. It is supported by the NIHR Biomedical Research Centre at the Oxford University Hospitals NHS Foundation Trust. Up to 30 patients will be enrolled.

David Fellows, Chief Executive Officer of Nightstar remarked: "We are delighted to report the advancement of this exciting gene therapy program into patients. If successful, this gene therapy has the potential to transform the lives of many patients (and their families) around the world."

Dr Aniz Girach, Chief Medical Officer of Nightstar commented: "The current trial is an open-label dose-escalation study designed to enrol at least 24 patients who will receive a single subretinal injection of the RPGR gene therapy. The primary goal of the study is to assess safety and tolerability of this gene therapy over a 12 month period."

Explore further: Mutations in CWC27 result in a spectrum of developmental conditions

An international team of researchers has discovered that mutations in the human gene CWC27 result in a spectrum of clinical conditions that include retinal degeneration and problems with craniofacial and skeletal development. ...

Silencing a gene called Nrl in mice prevents the loss of cells from degenerative diseases of the retina, according to a new study. The findings could lead to novel therapies for preventing vision loss from human diseases ...

Preceyes B.V., a spin-off of Eindhoven University of Technology, and Nightstar (UK) have entered into a collaboration for the development of a high-precision drug delivery technology in the eye. Nightstar will use the Preceyes ...

Using a new technology for repairing disease genesthe much-talked-about CRISPR/Cas9 gene editingUniversity of Iowa researchers working together with Columbia University Medical Center ophthalmologists have corrected ...

Researchers at UCL Institute of Ophthalmology and Moorfields Eye Hospital with funding from Fight for Sight, in collaboration with a team from Baylor College of Medicine in the USA, have discovered a new retinitis pigmentosa ...

Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness ...

New genes which help prevent prostate, skin and breast cancer development in mice have been discovered by researchers at the Wellcome Trust Sanger Institute and their collaborators. The study identified genes that cooperate ...

Like almost all light-sensitive living beings, human beings follow biological rhythms set on a period of about 24 hours. The circadian clock (from Latin "circa" and "dies", which means "about a day") therefore describes the ...

The majority of genes associated with nephrotic syndrome (NS) in humans also play pivotal roles in Drosophila renal function, a conservation of function across species that validates transgenic flies as ideal pre-clinical ...

Britain's Newcastle University says its scientists have received a license to create babies using DNA from three people to prevent women from passing on potentially fatal genetic diseases to their childrenthe first time ...

Columbia University Medical Center (CUMC) researchers have discovered a common genetic variant that greatly impacts normal brain aging, starting at around age 65, and may modify the risk for neurodegenerative diseases. The ...

Studies of autoimmune and inflammatory diseases have identified hundreds of genetic regions thought to be associated with these conditions. At the same time, studies of expression quantitative trait loci (eQTLs) have revealed ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post here:
New trial for blindness rewrites the genetic code - Medical Xpress

Read More...

Shining a light on face blindness – The Hippocratic Post (blog)

March 21st, 2017 1:46 am

Face blindness, or Prosopagnosis, is a common condition that affects aroundtwo in every 100 people in the UK, but relatively little is known about why it occurs and the psychological effect it has on peoples lives.

Researchers at Teesside University are hoping to raise awareness about this developmental disorder, which is an inability to recognise people from their facial features alone. In extreme cases, people cannot recognise family members and friends.

In extreme cases, people cannot recognise family members or friends.

Laura Sexton, a PhD student in Teesside Universitys School of Social Sciences, Business & Law, is carrying out research into face blindness with her supervisor, Dr Natalie Butcher, Senior Lecturer in Psychology. She says: Prosopagnosia affects people in different ways and for some they dont even realise it is a legitimate condition due to a general lack of awareness.

For others it can be very hard to cope with and leads to anxiety, stress, embarrassment and feelings of guilt.

Screening is important in that it allows us to develop a better understanding of the condition. First we need to determine if it is Prosopagnosia and not another underlying issue. Then we need to examine the severity of each case and find out peoples coping mechanisms and how it affects them psychologically.

The team have set up a screening centre, believed to be the first of its kind in the region, so that people who suspect they have the condition, can be tested for Prosopagnosia.

The team have set up a screening centre, believed to be the first of its kind in the region.

They are encouraging people who feel they may suffer from face blindness to come forward for screening tests in order to find out more about the condition.

People with face blindness often use non-facial cues to recognise others, such as their hairstyle, clothes, voice, or distinctive features. Many describe a fear and avoidance of social situations, such as family gatherings or meetings at work.

Thea Jourdan is the founder and editorial director of Hippocratic Post as well as being Editor of Apothecary, the journal of the Worshipful Society of the Apothecaries of London, and a contributor to the Good Health section of the Daily Mail. She sits on the executive committee of the Medical Journalists Association.

Read the rest here:
Shining a light on face blindness - The Hippocratic Post (blog)

Read More...

Exploring the cloud laboratory: biotechnology and cloud computing – Information Age

March 21st, 2017 1:46 am

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning

The continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.

Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment.

To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.

iland haveworked with many companies in the healthcare, life sciences and biotech industries. Therefore, it knowsfrom experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world.

>See also:10 trends that will influence cloud computing in 2017

For example, ilandrecently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the cloud. As a result, itsDR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.

If you still need convincing here are three additional key benefits that cloud brings to biotech organisations.

When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade.

These days, thanks largely to cloud technology, it can be done in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning.

Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.

Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing black box that obscures details needed to accurately interpret the results of computational analyses.

>See also:How cloud computing can transform the pharmaceutical industry

In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications.

Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.

Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily. For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed.

At the same time bio-technologists need to be able to access and share data across multiple departments or even multiple companies.

Cloud computing in biotechnology makes this all possible it centralises data, ensuring security and data sovereignty while facilitating collaboration.

It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.

Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues.

Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.

>See also:Managed cloud: making the most out of public cloud computing

As well as enhanced billing visibility and resource management functions, the release of the vendors secure cloud services means that the itscloud now includes on-demand security and compliance reports.

This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.

Without a shadow of a doubt, cloud technology can help biotechnology companies build the future. From research and development to marketing, computing affects everything an organisation does.

Sourced by Monica Brink, director of marketing, iland

Original post:
Exploring the cloud laboratory: biotechnology and cloud computing - Information Age

Read More...

The Brokerages Set Puma Biotechnology Inc (PBYI) PT at $70.50 – Petro Global News 24

March 21st, 2017 1:46 am

Puma Biotechnology Inc (NYSE:PBYI) has earned an average recommendation of Hold from the eight analysts that are covering the company. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $70.50.

Several brokerages have recently weighed in on PBYI. Royal Bank of Canada reissued a sector perform rating and issued a $17.00 price objective (down from $48.00) on shares of Puma Biotechnology in a research report on Thursday, March 2nd. Stifel Nicolaus reissued a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, November 30th. Citigroup Inc reissued a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Saturday, March 4th. Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research report on Tuesday, January 10th. Finally, Credit Suisse Group AG reissued an outperform rating on shares of Puma Biotechnology in a research report on Wednesday, January 18th.

Puma Biotechnology (NYSE:PBYI) opened at 44.15 on Tuesday. Puma Biotechnology has a 52-week low of $19.74 and a 52-week high of $73.27. The firms market capitalization is $1.63 billion. The firm has a 50-day moving average of $36.87 and a 200-day moving average of $43.70.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($2.04) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($1.92) by $0.12. On average, equities research analysts forecast that Puma Biotechnology will post ($8.32) EPS for the current fiscal year.

In related news, SVP Richard Paul Bryce sold 2,293 shares of the firms stock in a transaction dated Friday, January 20th. The shares were sold at an average price of $33.24, for a total transaction of $76,219.32. Following the transaction, the senior vice president now directly owns 29,237 shares of the companys stock, valued at $971,837.88. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert Charnas sold 3,008 shares of the firms stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $31.83, for a total transaction of $95,744.64. Following the transaction, the insider now directly owns 28,461 shares in the company, valued at $905,913.63. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,503 shares of company stock worth $511,078. 22.70% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. raised its position in Puma Biotechnology by 2.4% in the third quarter. UBS Asset Management Americas Inc. now owns 12,891 shares of the biopharmaceutical companys stock worth $864,000 after buying an additional 300 shares in the last quarter. California State Teachers Retirement System raised its position in Puma Biotechnology by 1.0% in the third quarter. California State Teachers Retirement System now owns 52,275 shares of the biopharmaceutical companys stock worth $3,505,000 after buying an additional 500 shares in the last quarter. BlackRock Investment Management LLC raised its position in Puma Biotechnology by 1.2% in the third quarter. BlackRock Investment Management LLC now owns 92,595 shares of the biopharmaceutical companys stock worth $6,208,000 after buying an additional 1,091 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical companys stock worth $163,000 after buying an additional 1,740 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in Puma Biotechnology by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,142 shares of the biopharmaceutical companys stock worth $618,000 after buying an additional 2,247 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Originally posted here:
The Brokerages Set Puma Biotechnology Inc (PBYI) PT at $70.50 - Petro Global News 24

Read More...

The Minneapolis Medical Research Foundation Selects Goodwin … – PR Newswire (press release)

March 21st, 2017 1:46 am

"For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development services and GMP manufacturing of a broad portfolio of Antibody:Drug Conjugate (ADC) and Protein:Drug Conjugate (PDC) projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody:Peptide Conjugates, Antibody:Dye Conjugates, PEGylated proteins, and other bioconjugates including Biobetters," said Muctarr Sesay, Ph.D., Chief Scientific Officer at Goodwin Biotechnology. "Our experience in Bioconjugation has resulted in several patents and publications, as well as proprietary processes that enable us to help our clients overcome some significant challenges in developing their next generation of bioconjugates. When including our experience in manufacturing vaccines for use in early- and late-stage clinical trials, we found the Minneapolis Medical Research Foundation project to be highly intriguing."

"This is not an unusual approach for us when we initiate a project because we collaborate with many of our clients in the early stages of proof of concept/development by empirically recommending the appropriate processes to create a viable ADC or PDC candidate," Dr. Sesay continued. "We then blend that with a solutions-oriented approach to help our clients overcome significant challenges to ensure that the process for their candidate is robust, compliant, economical, and scalable."

"We are proud to help advance the treatment for this growing public health concern because we're confident in the expertise that our highly skilled scientists have developed in the areas of ADCs and PDCs, based on the successful work that we have done with over 400 client projects over the last 24 plus years," said Karl Pinto, Chief Executive Officer at Goodwin Biotechnology, Inc. "Our Bioconjugation capabilities complement our experience in successfully developing and manufacturing monoclonal antibodies, recombinant proteins, and vaccines through mammalian cell culture expression systems. So, as part of our Single Source Solution, Goodwin is uniquely qualified to partner with our clients to meet their needs by developing customized and flexible approaches for manufacturing antibodies and recombinant proteins, for example, and / or design the appropriate conjugation activities to cost effectively deliver their product candidates on time."

About the Minneapolis Medical Research Foundation

The Minneapolis Medical Research Foundation (MMRF) is a subsidiary of Hennepin Healthcare System, Inc., and operates as the research arm of Hennepin County Medical Center, an acute care research and teaching hospital in Minneapolis. MMRF is one of the largest nonprofit medical research organizations in Minnesota and consistently ranks in the top 10 percent of all institutions receiving research funding from the National Institutes of Health. To learn more, visit mmrf.org.

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a uniquely qualified CDMO that offers a Single Source Solution for our clients from cell line development (through our strategic partner), exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody:Drug Conjugates (ADCs) for early and late stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with numerous companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has been awarded Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing in 2014.In addition, Goodwin Biotechnology was awarded 'Best in Sector: Biopharmaceutical Contract Development & Manufacturing' at Acquisition International magazine's 2015 Sector Performance Awards. Most recently, Goodwin Biotechnology received Global Health & Pharma's award for Best for BioProcess Development & cGMP Manufacturing in 2016, and Best in Mammalian Cell Culture Process Development & cGMP Manufacturing 2017. Click here to view the press releases!Additional information may be found at http://www.GoodwinBio.com.

Funding for this study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U01DA038876. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For more information, please contact:

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-minneapolis-medical-research-foundation-selects-goodwin-biotechnology-to-help-develop-and-manufacture-two-vaccines-to-treat-opioid-addiction-300426025.html

SOURCE Goodwin Biotechnology, Inc.

http://www.goodwinbio.com

Original post:
The Minneapolis Medical Research Foundation Selects Goodwin ... - PR Newswire (press release)

Read More...

‘Synthetic’ cartilage is now an option for big-toe arthritis sufferers – Detroit Free Press

March 21st, 2017 1:45 am

The Cartiva cartilage works like a bumper over the joints and is inserted into the base of the big-toe through a drilled hole. Courtesy of Cartiva

Karen Schumman, 51, of Chesterfield Township had a Cartiva implant put into her big toe on the left foot. She is photographed on March 17, 2017 at her home.(Photo: Mandi Wright, Detroit Free Press)Buy Photo

Orthopedic surgeon Dr. Matthew Brewster had long sought abetter treatment option for his younger,still-active patients suffering from arthritic joint pain in their big toe.

The gold standard for moderate to severe big-toe arthritis a fusion of the bones could relieve their painbut permanently rob them of mobility in the toe, limiting their ability to partake in athletic activities such as jogging and, for women, wearing heels.

"I didn't like fusing 55-year-old women'stoes that want to run and wear heels," said Brewster, who practices at Associated Orthopedists of Detroit and is affiliated with Beaumont Hospital in Grosse Pointe.

So when the U.S. Food and Drug Administrationlast July approved the first synthetic cartilage-like implant as a treatmentforbig-toe arthritis, he signed up. Brewster performed his firstprocedure with the Cartiva implant that month, helping a 62-year-old Clinton Township woman regain the ability to wear shoes without pain and even go running.

Read more:

Boy born without limbs in line for MSU-designed prosthetic

Study: Parenthood can boost your longevity

She became only the second U.S. patient to receivethe implant, which has been available in Europe for more than a decade. The first procedure was in Rochester, N.Y.

Brewster, the procedure's second U.S. doctor,has since successfully treated 13 patients with theimplant. All of them were relieved of their painand kept about half of their pre-arthritis joint mobility, he said.

Although the implant material is onlycurrently approved in the U.S. for the bigtoe,it has beensuccessfully usedto treatarthritic thumbs and knees in Canadaand Europe and offers hope for the millions ofarthritis sufferers who wish to remainactive and avoid jointreplacementsthat stealtheir mobility and require extensive surgeriesonce the deviceswear out.

An estimated 2.7 million middle-age people in the country right now have big-toe arthritis.

Brewster's patients'healthinsuranceagreed to cover the Cartiva implantand procedure costs, which aresaid to be slightly higher than a standard bone fusion.

"When he approached me with this, it sounded too good to be trueit's not," saidKaren Schumann, 51of Chesterfield Township,Brewster's most recent patient, whosebig-toe procedure was Feb. 22.

Dr. Matthew Brewster who practices at Associated Orthopedists of Detroit in St. Clair Shores and is affiliated with Beaumont Hospital, Grosse Pointe. He is the second doctor in the U.S. to do Cartiva implants.(Photo: Henry Ford Health System)

In an interview last week, Schumann recalled how her left toe had beenin increasingpainfor nearly 10 years and that she could no longerbend it. Now more than three weeks after the operation, her pain level is "zero," and sheonce again can go on long walks for exercise and go up and down stairs.

She hopes to have the same procedure done later this year on her right foot.

"I am so glad I had it done. You never realize how much you use the big toe until it hurts," Schumann said.

Headquartered outside Atlanta with 25 employees, Cartiva developed its Synthetic Cartilage Implant through research that originated out ofGeorgia Tech. The device is made of polyvinyl alcohol hydrogel, the same material as contact lenses, but is much thicker and the result ofapatented process that makes thematerial incredibly toughyet with a water content comparable to healthy cartilage. Eachimplantis expected to last many years, although the materialis still too new to makeprecise estimates.

Cartilage is a smooth,connective tissue that has a limited ability to repair itself if damaged. Researchers have been tryingfor decades to find a way to replace it. Degenerative arthritis occurs when cartilage gets worn away and bones then rubagainst each other.

"Synthetic cartilage or injectable cartilage or some type of implantable cartilage is definitely the Holy Grail of orthopedics," said Dr. Todd Irwin, a foot and ankle orthopedic surgeon at the University of Michigan Health Systemwho has done two Cartiva implant procedures.

"I think this is very promising," Irwin said, but added,"I think calling it synthetic cartilage is personally a little bit of a stretch. To me, functionally it's more of a bumper" between the bones.

Cartiva first introduced its hydrogel implantin Europe in 2002. But gaining FDA approval entailed more clinical trials and didn'thappen until last July.

Karen Schumman, 51, of Chesterfield Township had a Cartiva implant put into her big toe on the left foot. She is photographed on March 17, 2017 at her home.(Photo: Mandi Wright, Detroit Free Press)

Big-toe arthritis, known as hallux rigidus, isthe most common arthritic condition in the foot and said to affect 1 in 40 people older than 50, or roughly 2.7 million people in the U.S. Doctors say the problem can arise fromgenetics, past injuries orrepeated stress from work occupations such as flooring installation.

Yet only about 100,000 Americans each year the majority of them female getsurgical treatment for the condition, through fusions or typically metal joint implants. Those with less severe arthritis can find relief through a cheilectomy, which involves cleaning out the joint and removing bone spurs, althoughthat procedure currently rules out getting a Cartiva implant later on.

Doctors say the biggest problems with traditional implants for the big toe are therelatively high complication rates and how they often don't last beyond seven years.

The Cartiva cartilageworks like a bumper over the joints and is inserted into the base of the big-toe through a drilled hole.

Brewster said the procedure is relatively simple and takes him about 25 minutes. He considers it easier to perform than a traditional joint fusion of the toe, whichtakesmore than an hourand involves scraping out cartilage, packing in a cadaver bone graft,then screwing two bones together with a metal plate.

Patients are sedatedduring the procedure and afterward canactuallywalk out of the clinic. For two weeks theyare asked to wear a post-operative shoe, like a hard sandal. After that they can return to regularactivities.

A smallpeer-reviewed study of 27 Cartiva patients in Canada and the United Kingdom foundthat five years after theimplant,toe functionality had improved significantly in nearly everyone compared to before theirprocedure, the pain was significantly reduced and the synthetic cartilage was in good shape.

A full96% of the patients said they would undergo the procedure again.

Rosalynn Demers, 62, of Clinton Township was the first Michigan patient to receive the Cartiva implant.She had been enduring progressively worse big-toe pain for about a year and could nolonger wear most shoes because ofpain.

The Cartiva Synthetic Cartilage Implant was approved by the FDA in July 2016 to treat big-toe arthritis. (Photo: Cartiva)

"I thought it was a bunion, but it was arthritis. It was a gradual thing and then (the pain) just became ridiculous," she said. "I thought I as going to give all my shoes away, thinking that I'd never fit into them again."

She had planned to get a fusion, even thoughshe knew the procedurewould bringan end to her running hobby.Then she learned about the new FDA-approved synthetic cartilage option from her husband, Dr. Mike Demers, an orthopedic surgeon who is a colleague of Brewster's.

The Cartiva Synthetic Cartilage Implant was approved by the FDA in July 2016 to treat big-toe arthritis. (Photo: Cartiva)

In late July,Demers became the second person in the country to get theprocedure. Itwas asuccess. Not only is sheback to wearing almost all of hershoes, but she returned to running and evenraced in the Detroit Turkey Trot5K inNovember.

"I couldn't believe I ran the whole thing," she said. "It wasn't fast, but I ran it. So I thought that was pretty incredible."

Schumann, theChesterfield Township woman who just had theprocedure,recalled howBrewster demonstrated the new pain-free range of motion in her toe during a check-up appointment. Prior tothe operation, asudden movement like that would have causedsearing pain.

"All of the sudden, he bends my toe all the way down and I'm like, 'What!'" Schumann said. "He says, 'Does that hurt?' and I go, 'No you just scared me.' My toe has not been bent like that in years."

The list price of each Cartiva implant is $4,500, although hospitals can get a discount from the company.

A Beaumont representative said the Grosse Pointe hospital'stotalchargesfor the Cartiva procedure average$15,000 to $17,000. Insurance companiesthen typically pay around33% of the charges, or about $5,000, leaving the hospital to writeoff the remaining balance. Thosecharges donot include the surgeons fee, which is billed separately to insurance.

Nationwide, the averagebig toe-fusion is billed at $10,000 to $11,000 before insurance not including the surgeon's bill, according to James Laskaris, an emerging technologies senior analyst at MD Buyline, a Dallas-based firmthat provides clinical and financial information to hospitals. The surgeon istypically a $3,000 to $4,000 separatecharge, Laskaris said.

In addition tobig toes, doctors in Europe and Canada have had success using Cartiva implants to treat arthritic thumbs and knees.

Dr. Philip Sauve in the U.K. said he has treated 12 patients with thumb arthritis with a Cartiva implant. All had good results, he said.

"Thepain is reducing, their grip strength is increasingand so their function is improving," Sauvesaid in a phone interview. "So for that group who maybe is still working and still very active, I think it's a really good option."

Contact JC Reindl: 313-222-6631 or jcreindl@freepress.com. Follow him on Twitter@JCReindl.

Read or Share this story: http://on.freep.com/2numr43

See more here:
'Synthetic' cartilage is now an option for big-toe arthritis sufferers - Detroit Free Press

Read More...

Arthritis can’t stop art – Kankakee Daily Journal

March 21st, 2017 1:45 am

Kankakee Daily Journal
Arthritis can't stop art
Kankakee Daily Journal
Linda Randall-Powles had stage 4 arthritis, a disease that would inhibit many from being able to paint. Nonetheless, she never let it get in her way. "I have never known anyone so seriously afflicted with arthritis as Linda, yet she never complained ...

Read more here:
Arthritis can't stop art - Kankakee Daily Journal

Read More...

Nonprofit roundup: Courses on managing diabetes begin March 28 in Missoula – The Missoulian

March 20th, 2017 12:48 am

The Resource Center at Missoula Aging Services (MAS) is partnering with the MSU Extension Office and others to offer a six-week course for older adults with diabetes or pre-diabetes. The Diabetes Empowerment Education Program (DEEP) is available free to Medicare participants and their caregivers.

Classes will help people with diabetes learn how to take charge of their health and get control of the disease. While they are designed for older adults with Medicare, anyone with diabetes or pre-diabetes is welcome to attend. Courses will be held Tuesdays from 10 to 11:30 a.m., beginning Tuesday, March 28, and continuing through May 2, at the Missoula County Extension Office, 2825 Santa Fe Court.

Please call MAS at 406-728-7682 for more information or to register, or go to deepclasses.eventbrite.com to register online. Additional partners include Mountain-Pacific Quality Health, Everyone with Diabetes Counts (EDC), and the Montana Geriatric Education Center.

The YWCA Missoula invites you to LUNAFEST, a local event hosted by the GUTS! (Girls using their strengths) Program. GUTS! partners with LUNAFEST, an exciting national film festival featuring short films by, for and about women, to highlight the capacity, strength and beauty of women in film and young women of Missoula. This event will raise funds for our Summer Outdoor Adventure Trips and a smaller percentage for the Breast Cancer Fund. LUNAFEST will be held on Wednesday, April 19, at the Wilma Theater in downtown Missoula. Doors open for our silent auction at 6 p.m. and the show starts at 7 p.m. Tickets are $15 in advance, $18 day of show.

Child Care Resources training: Spring Conference is set for Saturday, April 1. How do we create rich environments that meet early childhood standards and allow children and their teachers to flourish?

As an active participant, sharing photos and discussing and brainstorming environmental successes and challenges in your child care program. Youll also create a design for one learning center that you can immediately begin to create in your program.

This conference will be held from 9 a.m. to 4 p.m. on Saturday, April, 1. This training is $25, and is worth six training hours.

Application workshops for anyone interested in applying to build a home in partnership with Habitat for Humanity of Missoula will be held Sunday, April 2, at 2 p.m. and Wednesday, April 5, at 7 p.m.

Workshops will be held in the conference room at the YWCA located at 1130 West Broadway.

No child care will be available at either meeting.

Applications will be available at the meetings. Access to our applications on our website or to pick up at our office will be available on Tuesday, April 4. Completed applications must be submitted by 5 p.m. on Friday, April 21.

Call 406-549-8210 for more information.

To help older adultswho want to get better control of their diabetes, Mountain-Pacific Quality Health, the Medicare Quality Innovation Network-Quality Improvement Organization (QIN-QIO) for Montana, Ag Worker Health & Services and the Montana Geriatric Education Center are partnering together to offer a series of six, free diabetes classes. These classes provide fun, informative and interactive ways to help people with diabetes or pre-diabetes (high blood sugar)

The classes support, not replace, professional diabetes self-management education. The classes are designed for people age 65 and older. Ag Worker Health & Services will make future announcements about any classes or events for those younger than 65.

The series kicks off Monday, April 17, from 5:30 to 6:30 p.m., at Ag Worker Health and Services at 9801 Valley Grove Drive #D, which is about a half mile north of Lolo on Highway 93. Classes will then meet every Monday through May 22. Anyone interested in attending theses classes can register by calling 406-273-4633.

Humanities Montana awarded a $900 grant to The Montana Racial Equity Project to support the Native American Race Relations and Healing Symposium. The day-long event will feature two panel discussions lead by authors, historians, language preservationists, and experts including John Robinson and Sterling HolyWhiteMountain. The first panel will focus on tribal sovereignty and the second will explore current issues facing the Native American population. The event will take place on Saturday, April 1, from 10 a.m. to 3 p.m., at the Native American Studies Building at the University of Montana.

Humanities Montana awarded a $1,000 grant to the Wedsworth Memorial Library to fund a monthly book discussion. Dr. Penny Hughes-Briant will host eight discussions from August 2017 to May 2018. All events will be held at the Wedsworth Memorial Library in Cascade.

Humanities Montana awarded a $1,000 grant to Columbus High School to fund the Yellowstone National Park Inquiry Project. Students will research and build projects on the impacts that visitors have on Yellowstone National Parks animals, ecosystem, environment, and cultural values.

Humanities Montana is the states independent, nonprofit state affiliate of the National Endowment for the Humanities.

View original post here:
Nonprofit roundup: Courses on managing diabetes begin March 28 in Missoula - The Missoulian

Read More...

Colorado Springs family adapts to reality of Type 1 diabetes as, one after one, children are diagnosed – Colorado Springs Gazette

March 20th, 2017 12:48 am

Siblings Melanie, McGuire, Emily and Ashley, all of whom have type 1 diabetes, goof off as parents Julie and Bubba Hayes watch at their home on Wednesday, February 1, 2017. Julie and Bubba Hayes have four out of five children with type 1 diabetes. Photo by Stacie Scott, The Gazette

It was a cold, wet California winter and Julie Hayes, her husband, Bubba, and their five kids all were laid low by a nasty stomach virus. When a week went by and 3-year-old Ashley hadn't rallied like her twin sister and the rest of the family, Hayes started to worry. The toddler was wetting the bed, which she hadn't done in at least a year, and though she ate nonstop, never seemed to get full. She'd sleep half the day and wake exhausted.

Hayes explained the examples of uncharacteristic behavior to the emergency room doctor, who peered into Ashley's eyes, had her stick out her tongue, and asked if diabetes ran in the family.

"I looked at him and said, 'I don't even know what diabetes is," Hayes said.

That, and life as she knew it, was about to change.

Over the following eight years, three more of her children would be diagnosed with Type 1 diabetes, a scenario that - even among families with a history of the disease - defies medical odds and, in many ways, illustrates the mysteries at the heart of genetic dynamics.

"I can tell you that the great majority of families have only one patient. Maybe 10 percent have two patients (and) there's just a handful of families with more than two," said Dr. Robert Slover, the Hayeses' physician and director of pediatrics at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus in Aurora. "That is an extremely unusual situation to have it happen to four children in a family."

For people with Type 1, formerly mislabeled "juvenile" diabetes, something - often a virus - kicks off a faulty immune system response that causes the body to attack the cells that produce the insulin needed to break down dietary carbohydrates and regulate blood sugar. As those cells die, the internal insulin machine becomes more and more compromised and eventually ceases to function.

"We are not exactly sure why the autoimmune process gets started, but the result is clear: The body turns on its own immune system to fight some common virus or agent and that destruction spills over," said Slover, whose center is home to one of the world's larger and more preeminent programs specializing in Type 1 diabetes research and care. "When that remaining group of cells shuts down, you go from maybe having enough (insulin) to be OK to not enough and having all the symptoms of diabetes."

A complex disease

As researchers stalk a cure and technological revolutions make management easier for those with the disease, the "why" of diabetes often remains elusive, the outcome of a complex equation and moving parts - genetic legacy and environmental influences - that, for now, can be answered only in theory.

"We know that people inherit a predisposition to the disease, then something in the environment triggers it ... but most who are at risk do not get diabetes," Slover said.

In people with a genetic risk of autoimmune ailments, research has identified a handful of factors that seem to affect the odds of them developing the disease, which emerges more often in winter and is more common in places with cold climates. Early diet may also play a role, as the disease is less common in people who were breastfed and who began eating solid foods at later ages. And though the evidence is more anecdotal than empirical, the increase in autoimmune diseases may have something to do with First World lifestyles, Slover said.

"In a less-sanitary America, there was a lot more exposure to animals, to foreign proteins and diseases, and people seemed to have almost a natural immunization," he said. "Statistics show that poorer nations that are less sanitary have a lower rate of developing Type 1 and other autoimmune diseases."

In the Hayeses' case, though, theories and statistics fall short.

"If a couple with the same genes had the same number of children, the odds are that most of the children wouldn't get all those same genes" that lead to the development of Type 1, Slover said. "The logic is backward - because it happened, it follows that the children must have inherited the predisposition."

Rising numbers

One thing Slover can say for certain is diabetes, and autoimmune diseases in general, are on the rise across the developed world. Over the past two decades, Type 1 diagnoses have increased at an annual rate of between 3 and 4 percent.

"Last year, we saw 450 newly diagnosed children. Ten years ago, it would have been more common to see 250," Slover said, adding that he's seen the greatest increase among toddlers and those over age 20, who today represent almost half of patients. "In pediatric populations, we used to talk about something of a peak in early adolescence - ages 7 to 13 - but these days I don't think that stands up."

Before insulin was discovered in 1921, diabetes had a grim prognosis. Most sufferers died in infancy or soon after manifesting symptoms; for those who didn't, a no-carb, starvation-level diet and rigorous exercise might buy an extra year. Today, pharmaceutical insulin is a miracle drug that allows an estimated 1.25 millions Americans to live out their otherwise natural clocks, so long as they adhere to a strict regimen of blood testing, injections and constant vigilance.

For a "D-mom" of four, it means life at DEFCON 2.

"You have to learn how to use insulin and regulate blood sugar when it's normally something your body does without you even thinking," said Hayes. "It makes you very nervous - can you even take care of your child?'"

On the ground, her and her husband's long-shot "bad collision of genes" is only vague context and background noise.

"Each child, each individual, this is their whole life," she said. "Each time . with each diagnosis . you're devastated all over again."

Telltale signs

A year after Ashley's diagnosis, the Hayes family was still adjusting to the new fulcrum of diabetes when her identical twin, Emily, began to exhibit similar symptoms.

She "just had this look," said Julie Hayes, who told her daughter she'd like to poke her finger, "like Ashley has to."

That evening, she called a family meeting to break the news. Ashley, who knew what it was like to have diabetes, immediately burst into tears; Emily's reaction, however, struck her mother as "kind of comical."

She was "just laughing and smiling and jumping up and down. Like, she got to be like her sister now," said Hayes, whose family moved to Colorado Springs in 2006. "It's terrible for them both to have it, but they have each other. It gave them a teammate and partner in diabetes, so it kind of seemed like it was meant to be."

The reception wasn't so enthusiastic when daughter Melanie was diagnosed, at age 11, after Hayes noticed telltale signs, such as extreme thirst, that her daughter's internal glucose regulation system was shutting down.

By the time McGuire was 14 and came downstairs complaining of feeling unwell and worried about his blood sugar, the hallmarks and lingo of diabetes were household knowledge. At the time, though, Mom chalked the complaint up to malingering. There was no way she had another child with Type 1.

"I was like, 'OK, whatever. Do your test, but as soon as you're done you're going to school,'" she said.

Constant vigilance

As parents to one, then two, then four children with Type 1 diabetes, Julie and Bubba Hayes learned to make do on a patchwork of sleep. Julie spent nights haunting the halls with a glass of juice and glucose monitor, poking fingers and checking blood sugar as her children slept. The kids got used to it; sometimes, they barely woke.

By the time Ashley and Emily were in their early teens and making a name for themselves on the bicycle motocross circuit, their mother thought everyone had a "pretty good handle" on diabetes. The twins, Melanie and McGuire all were on the insulin pump and had proven good stewards of their numbers. If they were feeling low at night, when the risk of blood sugar bottoming out is greatest, they'd wake up Mom so she could pour them some juice and tuck them back into bed.

In the fall of 2015, though, after a series of nights during which her blood sugar dropped to dangerous levels, daughter Emily had a hypoglycemic seizure.

"She was seizing and blue. I'd never experienced anything so scary in my whole life. Ashley was there, literally screaming her sister's name," said Hayes, who called for an ambulance to administer the life-saving injection of Glucagon, a substance that works quickly to raise blood sugar levels.

Hayes felt the old panic of uncertainty about her role, as parent - and sentry.

"It's a reality that people do die from this disease, from low blood sugar, and it happens mostly when they're sleeping," Hayes said. "Diabetes is so much scarier than we ever thought it was."

A better routine

Adolescence can be especially tough when compounded with the challenges of diabetes.

"Typically, worldwide, diabetes is hardest in the teenage years, not because teens are uncooperative but because they're growing and dealing with hormonal changes and that can be difficult," Slover said.

Today, all the Hayes children are teens except the oldest, 21-year-old Aubrey, who does not have diabetes (but, said Slover, remains at increased risk). New innovations play a vital part in managing day-to-day health.

After Emily's seizure, all began using a Dexcom continuous glucose monitoring system that keeps track of numbers using a subdermal sensor the size of two strands of hair and a 2-inch transmitter that can be worn for up to a week. In fact, the teens participated in trial research that helped usher the technology to federal approval late last year.

"Julie's incredible, and her interest in helping her own children - and helping us get a handle on that (diabetes in adolescence) - has been wonderful," said Slover, who continues to meet quarterly with the teens. "We owe a big debt of gratitude to all our patients helping us with that research."

With the new technology, rather than multiple finger-sticks each day the Hayes children need only test their blood sugar in the morning and at night, before bed, to calibrate the device. Results are transmitted to an iPhone app that issues alerts if blood sugar begins to move into critical ranges, low or high.

"You get a lot of alarms going off if it hits that point," Bubba Hayes said.

Not only does the technology help the Hayeses sleep more seamlessly, a feature allowing long-term tracking of glucose numbers has encouraged the children to improve their hemoglobin A1C, a measurement of blood sugar levels over a period of time.

The new setup expands the safety net for health maintenance into the digital realm. Users can chose up to five followers who also receive live data from their transmitter via a private social media app.

Seventeen-year-old Melanie Hayes' Dexcom network includes her mother, father, big sister and two best friends. "If I'm even slightly high, I start getting texts," she said. "My friend David will send me a text with an emoji for up or down. If I'm down, he'll say 'Hey, drink a juice.' That's really helpful."

-

Contact Stephanie Earls: 636-0364

Twitter: @earls_stephanie

Follow this link:
Colorado Springs family adapts to reality of Type 1 diabetes as, one after one, children are diagnosed - Colorado Springs Gazette

Read More...

Wins for Kansas: Juvenile Diabetes Research Foundation – KAKE

March 20th, 2017 12:48 am

WICHITA, Kan. (KAKE) -

Type 1diabetes is an autoimmune disease that can strike suddenly. The Juvenile Diabetes Research Foundation is working toward finding a cure, to help boys like Josh Dinkle.

Dinkle looked like any other little boy. But by age 13, he started displaying symptoms thatturned out to be type 1diabetes.

"It's so much more than people realize," Dinkle's mother Kim said.

Everything he drinks, eats and even emotescan cause his blood levels to crash.Like any good parent, Kim Dinkle monitorsher son's blood levels. She calls it a full-time job.

"You can't have a day off, a moment off. You check every moment what's going on with your blood sugar," she explained.

Each year, 40,000 Americans are diagnosed with type 1. The national non-profit group JDRFis on the front lines in the battle, and itsbig fundraiser is the "One Walk" event. The Wichita walk draws thousands, and raiseseven more.

Those donations translate into breakthroughs, according to organizerDe White."There was a time type 1was a death sentence. Now we are looking for our children to have a life sentence," White said.

With that in mind, KAKE'spartners at Wins for Kansas want to help. DeVaughn James Injury Lawyers provided a $500 grant, "to turn type 1e into type none."

If you'd like to register for the One Walk on Saturday, April 1, it's not too late. Click on this link for details.

Continue reading here:
Wins for Kansas: Juvenile Diabetes Research Foundation - KAKE

Read More...

The Affordable Care Act Helped With Type 2 Diabetes Treatments: One Woman’s Story – Reno Public Radio

March 20th, 2017 12:48 am

The nation is embroiled in the debate over the Affordable Care Act. The

Congressional Budget Office estimates that the GOP health bill could put 24 million Americans at risk of losing insurance. That has many local patients and doctors worried. Because of the ACA, more people were able to get health insurance and even access to life-saving treatments. One Reno woman shares her story with our reporter Anh Gray.

I meet Angela Siegfried at the Community Health Alliance Center For Complex Care on Wells Avenue in Reno. Its where she goes for health care. Siegfried has big, brown eyes and is full of optimism. Thats despite having to get around with the aid of an oxygen tank due to complications from Type 2 diabetes. These days Siegfried says shes grateful to have the oxygen. Before the Affordable Care Act, she was uninsured.

I would just get really sick and end up in the hospitals, emergencies, Siegfried explains, theyd keep me, get me a little bit well and send me on my way.

Siegfried says she was a loan officer but became too ill to work and eventually lost her insurance. Now shes receiving treatment at the community health center, which primarily serves low-income people.

Im an out of control diabetic; Im on insulin five times a day, pills, Siegfried says. Im on oxygen COP; Im ready to get a surgery thats called the sleeve so that my health will even be better. I wont be diabetic no more; I wont need oxygen.

Siegfried says her quality of life improved dramatically.

So as long as I have my oxygen, I go with my grandkids; I have three grandkidssix, seven, and eightlittle boys and they go to the park all the time and they wont go without me, Siegfried says about spending time with her grandsons. I get to go to soccer games, I get to go to church all the time. Im not just bedridden.

Oscar Delgado is a spokesman for Community Health Alliance where Siegfried receives her care. He also happens to be a City of Reno councilman.

Preventative care is all about getting ahead of it, right? Trying to make sure the person is taken care of and their health care needs are taken care of now or on the forefront, Delgado says.

In light of the current House Republican proposal to change the Affordable Care Act, Deglgado says hes concerned that some residents could lose access to care and the effect it would have on the community.

The ACA touches everything that we do here in the community one way or another, Delgado explains. In terms of, if peoples health care isnt taken care of, and they feel that they cant be taken of, the governments, the local governments starts to find a way of how they can provide a service.

Delgado says when people lack preventive care, problems persist. This could then trickle down to other areas like increasing the use of emergency care at hospitals, ambulatory care like REMSA, and even to other support services like the fire department.

Chuck Duarte, the CEO of Community Health Alliance, says hes worried that changes to the ACA would be a setback.

If it goes away, the chances are that those uncompensated costs are going to increase, Duarte points out, which means that those costs will shift to employer covered commercial insurance and their premiums will increase. It will affect everybody.

Duarte recalls a less than ideal health care environment prior to the ACA.

Its terrifying for a lot of families to have to face the fact that they may again be uninsured and have to face very large medical bills or not be able to pay for coverage, Duarte says.

Before Obamacare, almost a quarter of Nevadans were uninsuredthe second highest rate in the nation. Now were at about 11 percent.

For patients like Angela Siegfried, the possibility of losing coverage puts her on edge.

I dont ever want to be in this life without insurance. People who dont have insurance, I know what it feels like and its really sad because when youre sick and you cant go to the doctors and you cant get medications, Siegfried explains. Whats going to happen? The only thing, youre going to end up dying, and you probably could have prevented it. Yeah, Im a little nervous about it.

Helping Angela Siegfried get to her medical appointments is her daughter Nadine.

Back when we were without her having insurance, well, I almost lost her several times going to a diabetic coma. It became very serious. And me being an only child, I would have lost my mom, and I would have felt like Im in this world alone.

Siegfried plans to get healthy for her family. Nadine helps wheel her moms oxygen tank toward the medical front desk. Siegfried is eager to get her next medical appointment on the books.

Link:
The Affordable Care Act Helped With Type 2 Diabetes Treatments: One Woman's Story - Reno Public Radio

Read More...

Raising Awareness for Type One Diabetes in Naperville – Naperville Community Television

March 20th, 2017 12:48 am

Posted on March 19, 2017

12-year-old Naperville resident Paige Laurinec was diagnosed with type one diabetes when she was 8-years-old.

Everyday I wake up and I know what I have to do, during the day Ive adapted to carrying a purse with me to hold all my stuff, when lunch comes around I know I have to check and count all my carbs, explained Paige Laurinec.

Its what she and around 200,000 children who are diagnosed with type one diabetes endure everyday as the disease stops their pancreas from creating insulin. That means they need to replace it to maintain their health.

Insulin actually acts to lower your blood sugar it does a lot of different things to allow cells to uptake blood sugar and through multiple different activities it allows us to control our blood sugar, explained Dr. Jim Lengemann, Co-Medical Director of Edward Medical Group.

Local business owner Debbie Kliegl wanted to do her part to raise awareness of the disease and help find a cure. So she hosted a fundraiser donating 30% of all proceeds from Yogurt Beach on March 14 to help kids in our area that suffer from the disease.

We want to connect with our community and make a difference, we want people to understand were here for them, were a business, yeah,but were here to help the community. They help us and we help them, we want to work together, said Kliegl.

While doctors arent sure how long finding a cure may take, mothers of Paige and five-year-old Cayden, who also suffers from the disease, are hopeful more people will become educated about type one and help fund researchfor a cure.

A lot of people just dont know the difference, like oh if you eat too much sugar youll get diabetes, its really not true, especially with type one. I just pray for a cure everyday and I try to educate as much as I can and get involved as much as I can, said Sue Laurinec, Paiges Mom.

I know that were leaps and bounds further then we were years ago so were all hoping that for a cure. I dont know if were ever going to find it but we just choose to support it and hope that Cayden will see a cure in his lifetime, said Amy Nottke, Caydens Mom.

A sweet dream for the future.

Naperville News 17s Alyssa Bochenek reports.

See the article here:
Raising Awareness for Type One Diabetes in Naperville - Naperville Community Television

Read More...

Brit scientists testing ‘groundbreaking’ therapy that could cure … – The Sun

March 20th, 2017 12:45 am

The treatment is aimed at one of the most common causes of blindness in boys and young men

SCIENTISTS seeking a cure for blindness are testing a groundbreaking gene therapy on British patients.

The clinical trial aims to find a treatment for one of the most common causes of blindness in boys and young men.

Alamy

X-linked retinitis pigmentosa, allows the retinal cells to gradually stop working and eventually die, which prevents the eyes from processing light. There is currently no treatment available for sufferers. The trial, which could feature up to 30 patients, follows success by an Oxford

University team in treating those with another form of hereditary blindness, known as choroideremia.

Last Thursday a 29-year-old man with XLRP became the first patient to undergo the gene therapy procedure at Oxford Eye Hospital.

A virus carries corrective DNA into cells at the back of the eye.

For the treatment to work scientists have to reprogramme a gene called RPGR to make it more stable. The instability of that gene in the retina has previously been a major obstacle to finding a way of tackling the condition.

Prof Robert MacLaren, of Oxford University, said: We have spent many years working out how to develop this gene therapy.

Changing the genetic code is always undertaken with great caution, but the new sequence we are using has proven to be highly effective in our laboratory studies.

See more here:
Brit scientists testing 'groundbreaking' therapy that could cure ... - The Sun

Read More...

Doctors warn of ‘sneaky’ condition causing blindness – Starts at 60

March 20th, 2017 12:45 am

Dont miss what is right in front of you.

It is the message being shared as part of the Glaucoma Aware campaign, following World Glaucoma Week last week.

The Glaucoma Aware campaign aims to unearth 150,000 Australians who face preventable blindness and dont know it.

Glaucoma Australia reports more than 300,000 Australians have the condition but only half of those have been diagnosed.

According to the campaigns recent survey results conducted by Edelman Intelligence, around 60% of Australians either havent been tested or dont know if theyve been tested for glaucoma.

This is of great concern to Optometry Australia, which is on a mission to curb preventable eye disease through regular eye examinations.

80% of blindness in Australia is preventable, and with vision loss costing the economy $16.6 billionper year there are many reasons we should be looking after our most precious sense.

Optometry Australias resident optometrist, Luke Arundel said the motivation for getting an eye test often only comes when changes to vision are noted.

In some cases, thats shutting the gate after the horse has bolted. Luke Arundel

Read more: The vegetables that will keep your vision sharp.

Glaucoma is one of the sneaky conditions that can progress undetected without a check-up until significant amounts of vision are irreversibly lost.

Its an invisible, painless disease which affects our side vision, and because it often occurs in one eye first many people do not notice it in the early stages, as their good eye compensates for the vision loss in the other eye. The sad truth is that a lot of Australians are out there undiagnosed right now.

Because its nerve damage, theres no getting it back. But if we pick it up early, we can stop you losing more vision or stop you from going blind, so of course the earlier detection is made the better. More people can be assisted with reading, computer use and day to day tasks than previously, Mr Arundel said.

Read more: Macular degeneration and diet.

Age and family history are the biggest risk factors. According to National Health and Medical Research Council guidelines, glaucoma prevalence is four to ten times higher in people aged 60 years or older, compared to individuals in their 40s.

Relatives of glaucoma patients have a ten-fold increased risk of developing the disease2.

National guidelines encourage every Australian over the age of 50 to get a comprehensive eye examination to test for the early signs of glaucoma.

This video, launched for Glaucoma Week, shows the tragic loss of vision and precious moments which could have been saved by earlier detection.

To find an optometrist in your area visitgoodvisionforlife.com.au.

See original here:
Doctors warn of 'sneaky' condition causing blindness - Starts at 60

Read More...

The Amazing Technology Behind Colour Blindness Glasses – Women Love Tech (press release) (blog)

March 20th, 2017 12:45 am

An estimated 300 million people worldwide are colour blind men are more likely to be colour blind (eight per cent) while only 0.5 per cent of women are affected.

Its more accurate to say that most colour blind people are only partially colour blind, as they can still see colours, but they only see a narrow range of colours.

For decades, there have been glasses that claim to help the colour blind. They typically use a pink or reddish-tinted lens but its no different from looking through a pane of glass thats coloured red or pink.

But now there are colour blind glasses that feature sophisticated technology that has had astounding results.

EnChroma CEO Andy Schmeder told Women Love Tech, in the past, colour blind glasses have not been very effective.

They can help the colour blind do better on colour vision screening tests like the Ishihara test. However, such glasses simply create more contrast in colours because they emphasize one colour at the expense of another. The colour blind arent truly seeing more hues of colour and the glasses distort the colours they already see just fine. Essentially, they are similar to looking through a coloured pane of glass, Schmeder said.

EnChroma has revolutionised the technology behind colour blind glasses by creating a special patent-pending optical technology known as multi-notch filtering.

Red-green colour blindness is caused by an overlap of the green and red cones in the retina of the eye. EnChroma created the multi-notch filtering that removes small slices of light where the red and green cones in the retina overlap the most for the colour blind, Schmeder said. This re-establishes a more accurate ratio of light entering the three photopigments in the eye so the colour blind enjoy a more normal spectral response. The result is colour blind people experience enhanced colour, an improved ability to differentiate hues of colours, and better depth and detail perception.

The EnChroma glasses were researched through three US National Institute of Health (NIH) research grants and 10 years of R&D and clinical studies using scientific colour vision tests such as the D-15.

The glasses enhance the vibrancy and saturation of certain colours and improve colour discrimination, depth and detail perception without distorting the colours the colour blind already see well.

We hear from parents who tell us their child is now more confident in school because they can better see the colours in a social studies map or tell the difference when their teacher writes in red, green or purple marker on the board, Schmeder said.

Its amazing to see artists who use colour every day gain a better understanding or appreciation of the colours they routinely use. Some people see the red hair or green eye colour of a loved one or are simply transfixed that the grass in the yard of the home theyve been living in all their life has multiple hues of green in it instead of just one monochromatic dull green colour.

You can take the online colour blindness testto learn what type of red-green colour blindness you have and to learn the odds of EnChroma glasses helping you.

Go here to see the original:
The Amazing Technology Behind Colour Blindness Glasses - Women Love Tech (press release) (blog)

Read More...

Page 1,048«..1020..1,0471,0481,0491,050..1,0601,070..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick